HOMA-IR z-scores were associated with increased risks for incident lung disease, interstitial lung abnormalities, and ...

The phase III A DUE trial showed significantly greater pulmonary vascular resistance improvements with the fixed-dose ...

In patients with PAH, reducing peripheral serotonin using rodatristat ethyl negatively affects pulmonary hemodynamics and cardiac function.

The top articles about pulmonary arterial hypertension (PAH) in 2024 included FDA approvals, the effect of salt substitutes ...

In patients with familial PAH, SMAD5 appears to be a novel gene that warrants consideration for genetic testing, according to ...

INR:8341. praful patel Sotatercept for improving pulmonary vascular resistance received FDA breakthrough therapy designation Antengene's ATG-010 registration clinica ...

It also improves patients' exercise capacity and reduces pulmonary vascular resistance. These outcomes suggest the potential to extend patients' average life expectancy by over ten years when combined ...